Nagaraju Miriyala

6PUBLICATIONS
13CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Proteins and peptidesMolecular targetsPredictive and prognostic markersBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 20, 2026
Lipophilic Ligand Efficiency-Monitored Discovery of Potent, Achiral, and Bioavailable Apo-IDO1 Inhibitors.

|Feb 02, 2026
Discovery of Spiro[chromane-2,4'-piperidine] Derivatives as Irreversible Inhibitors of SARS-CoV-2 Papain-like Protease.

Qiangqiang Wei, Ashley J Taylor, Nagaraju Miriyala

|Aug 27, 2025
Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model.

James C Tarr, Kyuok Jeon, Nagarathanam Veerasamy

|Aug 05, 2024
Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors.

James C Tarr, James M Salovich, Martin Aichinger

|Nov 18, 2021
The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.

Wieslaw M Kazmierski, Nagaraju Miriyala, David K Johnson

|Mar 24, 2020
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.

Wieslaw M Kazmierski, Sam Baskaran, Jill T Walker

Pageof 1

Frequent Collaborators

3 joint publications

Wieslaw M Kazmierski

3 joint publications

Stephen W Fesik

2 joint publications

Harald Engelhardt

2 joint publications

Zachary O Gentry